<DOC>
	<DOCNO>NCT01517893</DOCNO>
	<brief_summary>The investigator purpose initiate phase II , randomize , placebo-controlled clinical trial test simvastatin , FDA-approved medication hypercholesterolemia , new treatment vitiligo . The aims placebo-controlled study seek determine safety potential efficacy simvastatin 80mg daily versus placebo adult male patient generalize vitiligo . Additionally , investigator collect blood examine effect simvastatin autoreactive CD8+ T cell vitiligo patient .</brief_summary>
	<brief_title>Clinical Trial Simvastatin Treat Generalized Vitiligo</brief_title>
	<detailed_description />
	<mesh_term>Vitiligo</mesh_term>
	<mesh_term>Simvastatin</mesh_term>
	<criteria>male gender age 1864 least one vitiligo skin lesion measure least 2x2 cm size willing able understand sign inform consent able complete study comply study procedure history segmental vitiligo allergy statin medication use statin medication due cardiac risk . use medication contraindicate use simvastatin use topical vitiligo treatment past 4 week use laser lightbased vitiligo treatment within past 8 week treatment immunomodulating oral medication past 4 week use statin medication past 8 week evidence hepatic dysfunction , personal family history nonalcoholic steatotic hepatitis , personal history hepatitis evidence renal dysfunction history myopathy rhabdomyolysis , elevate baseline creatinine kinase recent history alcohol drug abuse history diabetes untreated hypothyroidism condition require use interfering topical systemic therapy current condition might interfere study assessment , limited , atopic dermatitis psoriasis clinically significant abnormal finding condition might , opinion Principal Investigator , interfere study evaluation pose risk subject safety study .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>vitiligo</keyword>
	<keyword>simvastatin</keyword>
</DOC>